CompletedNot Applicable

Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada

Canada250 participantsStarted 2023-09-05

Plain-language summary

The purpose of this observational study is to describe the patient, disease and treatment characteristics of eligible participants with upper gastrointestinal cancer treated with adjuvant nivolumab.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Enrolled in Bristol-Myers Squibb GastroEsophageal Opdivo in Resected Patients with Residual Pathological Disease Patient Support Program (GEORge PSP) in Canada * Patients who have consented to the use of their de-identified data generated from information collected in the course of the GEORge PSP Exclusion Criteria: * Aged \<18 years * Did not receive concurrent chemoradiotherapy prior to surgery * Positive margins following resection * No residual disease following complete resection

What they're measuring

Participant sociodemographics

Timeframe: Baseline

Participant Eastern Cooperative Oncology Group (ECOG) score

Timeframe: Baseline

Participant histology results

Timeframe: Baseline

Participant comorbidities

Timeframe: Baseline

Participant tumour location

Timeframe: Baseline

Date of tumour resection

Timeframe: Baseline

Participant primary upper gastrointestinal cancer diagnosis

Timeframe: Baseline

Trial details

NCT IDNCT06361563

SponsorBristol-Myers Squibb

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-01-25

View on ClinicalTrials.gov More Upper Gastrointestinal Cancer trials